Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-leukemia effects of SR140333

A technology for blood cancer and its purpose is applied in the field of treating blood cancer in subjects, relieving symptoms of blood cancer in subjects or inhibiting the proliferation of blood cancer cells, and can solve the problems of neurotoxic release of histamine, weak effect, fast metabolism, etc.

Inactive Publication Date: 2011-09-21
ZHEJIANG SCI-TECH UNIV
View PDF5 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The first generation of antagonists starts with changing tachykinin amino acids, and substitutes D-amino acids to obtain some antagonistic polypeptides, but their effects are weak, their selectivity is low, and they have neurotoxicity and release histamine.
The second-generation antagonists are short peptide and cyclic peptide antagonists with high affinity and high selectivity obtained on the basis of shortening the peptide chain and chemical modification, but their oral bioavailability is low and metabolism is fast

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-leukemia effects of SR140333
  • Anti-leukemia effects of SR140333
  • Anti-leukemia effects of SR140333

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0032] 1. Materials and Methods

[0033] 1.1 Materials, instruments and reagents

[0034] 1.1.1 Cell lines

[0035] Human chronic myeloid leukemia cells K562 and mouse erythroleukemia MEL cells were purchased from the Chinese Academy of Medical Sciences Tumor Cell Bank. Antagonist SR140333 of neurokinin receptor 1 was provided by Sanofi-Synthelabo, France.

[0036] 1.1.2 Main reagents

[0037] DMEM medium Gibco company

[0038] FBS Hyclone

[0039] DMSO Sigma-Aldrich

[0040] 1.1.3 Reagent preparation

[0041] Phosphate buffer saline (PBS): 8g sodium chloride, 0.2g potassium chloride, 2.9g disodium hydrogen phosphate, 0.2g potassium dihydrogen phosphate, 1L deionized water, store at 4°C.

[0042] SR140333 was first dissolved in DMSO, then added to PBS to make 9×10 -3 Mother liquor of M. The concentration of DMSO in the working solution is less than 1%. The prepared mother liquor was sterilized by filtration with a 0.22 μm filter membrane, then dispensed into 1.5 mL E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to anti-leukemia effects of a neurokinin receptor antagonist SR140333, and relates specifically to methods of treating leukemia and relieving leukemia symptoms for subjects, to a method of inhibiting a proliferation of leukemia cells, to uses of the neurokinin receptor antagonist in drugs, medicaments or pharmaceutical compositions utilized for treating leukemia and relieving leukemia symptoms, or inhibiting a proliferation of leukemia cells, and to a pharmaceutical product comprising a neurokinin receptor antagonist as an active ingredient and a specification of the pharmaceutical product.

Description

technical field [0001] The present invention relates to the anti-blood cancer effect of neurokinin receptor antagonists. Specifically, the present invention relates to: methods for treating blood cancer in a subject, alleviating symptoms of blood cancer in a subject, or inhibiting proliferation of blood cancer cells; antagonists of neurokinin receptors are used in the preparation of blood cancer, alleviating symptoms of blood cancer or inhibiting blood cancer Use in a drug, medicament or pharmaceutical composition for cell proliferation; and a pharmaceutical product comprising an antagonist of a neurokinin receptor as an active ingredient and instructions relating to the pharmaceutical product. Background technique [0002] Cancer is a kind of disease that seriously endangers human health. At present, the global cancer death toll is higher than the sum of the death toll from AIDS, tuberculosis and malaria, and it has become the number one killer in the world. The number of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4545A61P35/02
Inventor 付彩云赵辅昆张世馥王宇沙陈攀峰
Owner ZHEJIANG SCI-TECH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com